Orforglipron vs Dapagliflozin in Type 2 Diabetes: What the ACHIEVE-2 Trial Found 24th September 202611th July 2026 by Living Diabetes Editorial ACHIEVE-2 compared oral orforglipron with dapagliflozin in adults with type 2 diabetes. Learn about HbA1c, weight, side effects, and study limits.
SGLT2 Inhibitors: Heart and Kidney Protection Beyond Glucose 3rd June 202621st March 2026 by Living Diabetes Editorial Team SGLT2 inhibitors can protect heart and kidney health in selected people, but they also need clear sick-day and safety guidance.
